Vocera Communications
2022
$3.0B
Stryker
Acquisitions
4
Major Deals Covered
$12.1B
Disclosed Deal Value
Stryker's largest disclosed acquisition here is Wright Medical Group for $4.7 in 2020. This page covers 4 major deals from 2013 to 2022, each with its price where disclosed and the reason behind it.
| Company | Year | Price | Purpose |
|---|---|---|---|
| 2020 | Undisclosed | Extremities and trauma market leadership in upper and lower extremities and biologics. | |
| 2022 | Undisclosed | Hands-free clinical voice communications and smartphone smart alert software for hospitals. | |
| 2013 | Undisclosed | Pioneering robotic-arm assisted joint arthroplasty platform for knees and hips. | |
| 2016 | Undisclosed | Single-use disposable products that prevent hospital-acquired infections and surgical site contamination. |
2022
$3.0B
2020
$4.7B
2016
$2.8B
2013
$1.6B
Under CEO Kevin Lobo, Stryker is pursuing four core growth vectors: (1) Expanding Mako Indications: Commercializing Mako Spine and Mako Shoulder robotic capabilities to capture multi-billion-dollar adjacencies in outpatient surgery centers; (2) Driving Ambulatory Surgery Center (ASC) Penetration: Developing specialized, capital-efficient implant bundles and robotic programs tailored for the rapidly growing shift of joint replacement surgeries from inpatient hospitals to outpatient surgical suites; (3) Scaling International Expansion: Increasing market share across Europe, Japan, China, and Latin America where robotic orthopedic adoption is still in early stages; and (4) Digital Care Coordination via Vocera: Integrating smart hospital beds (ProCuity), hands-free wearable communication badges, and nurse call systems to prevent patient falls and automate clinical alerts.
Stryker operates a highly durable, diversified medtech business model spanning surgical consumables, capital equipment, and implantable medical devices: (1) MedSurg and Neurotechnology (~58% of revenue / ~$11.9B), generating high-margin revenue from surgical power tools, endoscopes, Neptune waste management systems, emergency stretchers, and Vocera clinical software; (2) Orthopedics (~42% of revenue / ~$8.6B), monetizing proprietary titanium hip and knee implants, trauma fixation plates, extremities devices, and Mako robotic consoles; and (3) Razors-and-Blades Capital Equipment Model: Stryker installs multi-hundred-thousand-dollar capital systems (Mako robots, operating room visualization towers, hospital beds) that drive continuous, recurring daily utilization of single-use surgical cutting blades, sterile drapes, burrs, and implant components. Stryker maintains gross margins near 66% and operating cash flow exceeding $3.7 billion.
Stryker pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
Transformative transactions in Stryker's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
Stryker deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Yes, Stryker periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Compare corporate acquisition records, deal values, and strategic targets
Explore Stryker
Core profile pages, founders and related research hubs for this company.